Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labiana HealthXMAD:LAB -0.75%57 Cash-to-Debt is 0.16 as of Dec. 2025, which is 129% above its 10-year median of 0.07. GuruFocus rates XMAD:LAB with a GF Score™ of 57/100 and a GF Value™ of €3.59 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 989 Drug Manufacturers companies, Labiana Health ranks worse than 80.79% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Labiana Health's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.16.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Labiana Healthcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Labiana Health's Cash-to-Debt or its related term are showing as below:
XMAD:LAB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 0.07 Max: 0.19
Current: 0.16
During the past 6 years, Labiana Health's highest Cash to Debt Ratio was 0.19. The lowest was 0.06. And the median was 0.07.
XMAD:LAB's Cash-to-Debt is ranked worse than 80.79% of 989
companies
in the Drug Manufacturers industry
Industry Median: 1
vs XMAD:LAB: 0.16
Labiana Health (XMAD:LAB) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Labiana Health Cash-to-Debt Related Terms
Labiana Health Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Labiana Health's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
XMAD:LAB vs ZTS, UTHR, VTRS: Cash-to-Debt Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labiana Health's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labiana Health Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labiana Health's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Labiana Health's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labiana Health (XMAD:LAB) has a Cash-to-Debt of 0.16 as of Dec. 2025. This is 129% above median its historical median of 0.07. Over the past decade, Labiana Health's Cash-to-Debt has ranged from 0.06 to 0.19. According to the industry distribution chart, Labiana Health ranks #799 out of 989 companies in the Drug Manufacturers industry, placing it in the top 80.8%.
Is Labiana Health's Cash-to-Debt too high?
Labiana Health's current Cash-to-Debt of 0.16 is 129% above median its 10-year median of 0.07. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.19. The Drug Manufacturers industry median Cash-to-Debt is 1.00. Labiana Health's value of 0.16 is 84% below this industry median. Based on the distribution chart, Labiana Health ranks #799 out of 989 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Labiana Health has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Labiana Health's Cash-to-Debt compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labiana Health ranks #799 out of 989 companies for Cash-to-Debt. This places Labiana Health in the lower half of its industry. The industry median Cash-to-Debt is 1.00. Labiana Health's value of 0.16 is 84% below this benchmark. Historically, Labiana Health's own Cash-to-Debt has ranged from 0.06 to 0.19 over the past decade. While the company's 10-year median is 0.07 vs. the industry median of 1.00, Labiana Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 1.00, based on 989 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labiana Health's current Cash-to-Debt of 0.16 is 84% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 1.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labiana Health's current Cash-to-Debt is 0.16, which is 129% above median its own 10-year median of 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labiana Health stock overvalued right now?
Based on GuruFocus' analysis, Labiana Health (XMAD:LAB) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €6.60 — trading 83.8% above its estimated fair value. The current Cash-to-Debt is 0.16, which is 129% above median its 10-year median of 0.07 and 84% below the Drug Manufacturers industry median of 1.00. Labiana Health's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Labiana Health (XMAD:LAB), the current Cash-to-Debt is 0.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labiana Health (XMAD:LAB) Overvalued in 2026?
Based on GuruFocus' analysis, Labiana Health stock appears to be overvalued.
The current stock price of €6.60 is trading 83.8% above its estimated GF Value™ of €3.59.
GuruFocus considers Labiana Health to be Significantly Overvalued.
Key valuation signals for XMAD:LAB:
Cash-to-Debt: 0.16 (129% above median its 10-year median of 0.07)
GF Value™: €3.59 vs. price of €6.60 (83.8% above fair value)
Industry Position: 84% below the Drug Manufacturers median (#799 of 989)
No single metric tells the full story. See the XMAD:LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labiana Health SA is a manufacturer of pharmacological products for veterinary use. The company's activities include a GMP manufacturer for EU animal and human health industries, a manufacturer specializing in sterile and lyophilized dosage forms, and a source of development, acquisition, and licensing of molecules such as Fosfomycin Trometamol. The company operates in two segment Animal Health and Human Health.
57GF Score
Get the complete analysis for XMAD:LAB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:LAB has been successfully added to your 
